Drugs / Isunakinra
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07698106 | Aug 2026 → Aug 2034 expected | triple-negative breast carcinoma | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04121442 | Sep 2020 → Dec 2023 | cancer | Buzzard Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06634875 | Jan 2025 → Jun 2026 overdue | colorectal cancer | Buzzard Pharmaceuticals | Recruiting | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT02082899 Comparator | Feb → Jun 2014 | conjunctivitis | Eleven Biotherapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02492321 Comparator | Jul → Nov 2015 | conjunctivitis | Eleven Biotherapeutics | Completed | No outcome recorded |
| Phase 3 | NCT02405039 Comparator | Apr 2015 → Jun 2016 | dry eye syndrome | Eleven Biotherapeutics | Unknown | No outcome recorded |
| Phase 3 | NCT01998802 Comparator | Jan 2014 → Mar 2015 | dry eye syndrome | Eleven Biotherapeutics | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isunakinra | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04121442 ↗ |
| Known as | EBI-005 | “isunakinra (EBI-005), a modified recombinant IL1 receptor antagonist” NCT07698106 ↗ |
| Action | Inhibit | “potently blocks IL-1 alpha and IL-1 beta signaling” NCT04121442 ↗ |
| Modality | Protein / enzyme biologic | “Isunakinra is a recombinant protein” NCT04121442 ↗ |
| Route | Topical | “5 mg/mL topical administered 3 times per day.” NCT01998802 ↗ |
| Target | IL1R1 | “binds to the IL1R1” NCT04121442 ↗ |